Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Lactobacillus rhamnosus HN001

What does the research say about Lactobacillus rhamnosus HN001?

3 health outcomes synthesised

Lactobacillus rhamnosus HN001 is a probiotic strain studied primarily for its effects on anxiety, eczema, and atopic sensitization across 3 health outcomes. The strongest evidence area is reduced anxiety, with 3 of 4 studies reporting beneficial effects, predominantly in pregnant and postpartum women over a median study duration of 2 years. A typical dose used across outcomes is 6 × 10^9 CFU daily, though evidence remains limited overall.

Strongest evidence: The most researched outcome for Lactobacillus rhamnosus HN001 is reduced anxiety, where 3 of 4 studies reported beneficial effects with small to moderate effect sizes. Evidence strength is low, but the consistency is notable. All studies were conducted in pregnant or postpartum women, with one study showing effects over 2 years of supplementation.

Mixed or weaker evidence: For reduced eczema prevalence, only 1 of 3 studies found a beneficial effect (large-sized), while 2 reported neutral findings. Evidence is low-strength and preliminary. For reduced prevalence of atopic sensitization, all 3 studies reported neutral small effects, with no statistically significant results.

Effective dose patterns: Across outcomes, the most consistent dose is 6 × 10^9 CFU daily. This dose was used in studies on eczema and atopic sensitization, while anxiety studies did not report a standardized effective dose.

Population insights: Research primarily involves pregnant and breastfeeding women, postpartum women, and their infants, often from high-risk birth cohorts for allergic disease. Benefit for eczema and atopic sensitization appears to depend on supplementation of both mother and child from late pregnancy through early childhood.

Notable caveats: All outcomes have a small evidence base (3–4 studies each), and overall evidence strength is low. Publication bias may inflate positive findings for anxiety. Many studies did not reach statistical significance, and neutral results suggest effects may be population-specific or smaller than initial studies suggest.

Frequently asked

  • What is Lactobacillus rhamnosus HN001 good for according to research?
    Research on Lactobacillus rhamnosus HN001 has focused on three outcomes: reduced anxiety, reduced eczema prevalence, and reduced atopic sensitization. The most consistent findings are for reduced anxiety, with 3 of 4 studies reporting beneficial effects, primarily in pregnant and postpartum women.
  • What dose of Lactobacillus rhamnosus HN001 is typically used in studies?
    The most studied dose is 6 × 10^9 CFU daily. This dose was used in trials on eczema and atopic sensitization. Anxiety studies did not consistently report a specific effective dose.
  • Who benefits most from Lactobacillus rhamnosus HN001?
    The strongest evidence is in pregnant and postpartum women for anxiety reduction. For eczema and atopic sensitization, benefits may depend on supplementation of both mothers and infants from late pregnancy through early childhood, particularly in high-risk birth cohorts for allergic disease.
  • Are there caveats or limitations in the research on Lactobacillus rhamnosus HN001?
    Yes. The evidence base is very small (3–4 studies per outcome) and all findings are considered low-strength. Publication bias may overestimate benefits for anxiety. Many studies did not reach statistical significance, and neutral results suggest effects may be small or population-specific.
  • Does Lactobacillus rhamnosus HN001 help with anxiety?
    Three of four studies reported beneficial effects on anxiety, with small to moderate effect sizes, all in pregnant and postpartum women. However, the evidence is low-strength and the results should be considered preliminary due to the small number of studies and potential publication bias.
  • Does Lactobacillus rhamnosus HN001 reduce eczema?
    Only 1 of 3 studies found a beneficial effect on eczema prevalence, with a large effect size. Two studies reported neutral findings. Evidence is low-strength, and benefit may depend on supplementing both mothers and children from late pregnancy through age 2 years.

Most-studied combinations with Lactobacillus rhamnosus HN001

most supplement research is combination research
Also studied with:Bifidobacterium lactis HN019 (3), Lactobacillus rhamnosus MAK79L08R (2), Bifidobacterium longum BB536 (2), Bifidobacterium animalis subsp. lactis HN019 (2)
Back to top